Get started
Author

Ge Lou

Observed names: G. Lou, G.e. Lou, GE LOU, 娄阁
ORCID: 0000-0001-5405-7406
Observed ORCID: 0000-0001-5405-7406
OpenAlex ID: A5100684538
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
2023 · Ning Li, Jianqing Zhu, et al. · JAMA Oncology · 176
PDF
Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model
2019 · Chang Yang, Bai-Rong Xia, et al. · Cancer Cell International · 136
PDF
Organoids: An intermediate modeling platform in precision oncology
2017 · Ming-Zhu Jin, Run-Run Han, et al. · Cancer Letters · 94
Comprehensive analysis of the SLC16A gene family in pancreatic cancer via integrated bioinformatics
2020 · Shan Yu, Yanshuang Wu, et al. · Scientific Reports · 61
PDF
miR-181a-5p Promotes Proliferation and Invasion and Inhibits Apoptosis of Cervical Cancer Cells via Regulating Inositol Polyphosphate-5-Phosphatase A (INPP5A)
2017 · Meng Yang, Xu Zhai, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 59
Pamiparib Monotherapy for Patients with Germline BRCA1/2 -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
2021 · Xiaohua Wu, Jianqing Zhu, et al. · Clinical Cancer Research · 43
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma
2014 · Lina Gu, Bairong Xia, et al. · Tumor Biology · 39
Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection
2013 · Dan Kong, Di Wu, et al. · International Journal of Infectious Diseases · 36
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells
2016 · Ting-Ting Ge, Meng Yang, et al. · Journal of Ovarian Research · 33
PDF
Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer
2014 · WENGUANG MA, KUN WANG, et al. · Molecular Medicine Reports · 32
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
2023 · Lingfang Xia, Jing Wang, et al. · International Journal of Gynecological Cancer · 31
PDF
E2F1/2/7/8 as independent indicators of survival in patients with cervical squamous cell carcinoma
2020 · Chang Yang, Zhao-Cong Zhang, et al. · Cancer Cell International · 31
PDF
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
2024 · Xiaohua Wu, Jianqing Zhu, et al. · EClinicalMedicine · 28
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
2023 · Yaxin Liu, Wei Wang, et al. · BMC Medicine · 22
PDF
Evaluation of Chemotherapy Response with Serum Squamous Cell Carcinoma Antigen Level in Cervical Cancer Patients: A Prospective Cohort Study
2013 · Mingzhu Yin, Yan Hou, et al. · PLoS ONE · 20
PDF
The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
2021 · Chang Yang, Ge Lou, et al. · Signal Transduction and Targeted Therapy · 17
PDF
Endoscopic transcecal appendectomy: the first human case report
2017 · Bing-Rong Liu, Ji-Tao Song, et al. · Gastrointestinal Endoscopy · 16
Distinct clinicopathological features of pulmonary primary angiomatoid fibrous histiocytoma: A report of four new cases and review of the literature
2020 · Zheng Wang, Liping Zhang, et al. · Thoracic Cancer · 14
PDF
An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance
2018 · Kai Yang, Weiwei Zhao, et al. · Frontiers in Immunology · 10
PDF
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
2024 · Huayi Li, Zikun Peng, et al. · BMC Medicine · 8
First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study
2024 · Jing Li, Youguo Chen, et al. · Frontiers of Medicine · 6
USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression
2025 · Dejia Chen, Yue Zhao, et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 5
LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
2020 · X. Wu, J. Zhu, et al. · Annals of Oncology · 5
E2F8 Knockdown Suppresses Cell Proliferation and Induces Cell Cycle Arrest via Wnt/β-Catenin Pathway in Ovarian Cancer
2023 · Meiyin Zhang, Ye Xu, et al. · The Chinese Journal of Physiology · 4
34 Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 trial
2024 · Xiaohua Wu, Jianqing Zhu, et al. · International Journal of Gynecological Cancer · 3
Works count: 46
Citation count: 944
H-index: 16
I10-index: 19
Year
Topic
Type